Genixus, a United States-based pharmaceutical company, has named Seth Coombs as its new chief commercial officer and Don Anthony JD PhD as its new executive vice president, global head of Intellectual Property, it was reported on Tuesday.
Prior to joining Genixus, Coombs has served Novartis in roles of increasing responsibility across three divisions. He has held the position of vice president, Commercial Operations & Alliance Management at Novartis' Sandoz division. He has also served as vice president, Oncology and Injectable products for Sandoz US and held several senior roles within Novartis Vaccines and Diagnostics.
Dr Anthony is an attorney focused on intellectual property and commercial pharmaceutical law. He has held various roles of increasing responsibility at various pharmaceutical companies, which includes senior vice president of Intellectual Property at Mayne Pharma.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses